Beginning a New Era of Precision Alzheimer’s Therapeuticsalzheon2024-04-02T18:48:02-04:00April 2nd, 2024|
Newsweek Investment Report: Interview with Dr. Martin Tolar, President & CEO of Alzheon, Inc. January 2024alzheon2024-01-12T14:46:41-05:00January 11th, 2024|
ALZ-801 for 2 years seen to sustain cognition in early Alzheimer’salzheon2023-10-02T11:49:22-04:00September 22nd, 2023|
Alzheimer Agent ALZ-801 Improves Cognition, Reduces Relevant Biomarker Levels in 2-Year Analysisalzheon2023-09-21T10:37:23-04:00September 18th, 2023|
AAIC: A Pill to Slow Down Alzheimer’s Is About Two Years Awayalzheon2023-07-18T10:41:12-04:00July 16th, 2023|
Venture Capitalists Fund New Generation of Alzheimer’s Drugsalzheon2023-07-17T08:39:58-04:00July 13th, 2023|
Understanding Patient Characteristics of Phase 3 APOLLOE4 Trial of ALZ-801 in Alzheimer Disease: John Hey, PhDalzheon2023-05-31T18:05:53-04:00May 10th, 2023|